Table of Contents

1 HIV Therapy Market Overview

• 1.1 Product Overview and Scope of HIV Therapy
• 1.2 HIV Therapy Segment by Drug Type
  • 1.2.1 Global HIV Therapy Sales Growth Rate Comparison by Drug Type (2022-2028)
  • 1.2.2 Integrase Inhibitors
  • 1.2.3 Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 1.2.4 Combination HIV Medicines
  • 1.2.5 Others
• 1.3 HIV Therapy Segment by Application
  • 1.3.1 Global HIV Therapy Sales Comparison by Application: (2022-2028)
  • 1.3.2 Hospital Pharmacies
  • 1.3.3 Retail Pharmacies
  • 1.3.4 Online Pharmacies
  • 1.3.5 Others
• 1.4 Global HIV Therapy Market Size Estimates and Forecasts
  • 1.4.1 Global HIV Therapy Revenue 2017-2028
  • 1.4.2 Global HIV Therapy Sales 2017-2028
  • 1.4.3 HIV Therapy Market Size by Region: 2017 Versus 2021 Versus 2028

2 HIV Therapy Market Competition by Manufacturers

• 2.1 Global HIV Therapy Sales Market Share by Manufacturers (2017-2022)
• 2.2 Global HIV Therapy Revenue Market Share by Manufacturers (2017-2022)
• 2.3 Global HIV Therapy Average Price by Manufacturers (2017-2022)
• 2.4 Manufacturers HIV Therapy Manufacturing Sites, Area Served, Product Type
• 2.5 HIV Therapy Market Competitive Situation and Trends
  • 2.5.1 HIV Therapy Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest HIV Therapy Players Market Share by Revenue
  • 2.5.3 Global HIV Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 HIV Therapy Retrospective Market Scenario by Region

• 3.1 Global HIV Therapy Retrospective Market Scenario in Sales by Region: 2017-2022
• 3.2 Global HIV Therapy Retrospective Market Scenario in Revenue by Region: 2017-2022
• 3.3 North America HIV Therapy Market Facts & Figures by Country
  • 3.3.1 North America HIV Therapy Sales by Country
  • 3.3.2 North America HIV Therapy Revenue by Country
  • 3.3.3 United States
  • 3.3.4 Canada
• 3.4 Europe HIV Therapy Market Facts & Figures by Country
  • 3.4.1 Europe HIV Therapy Sales by Country
  • 3.4.2 Europe HIV Therapy Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific HIV Therapy Market Facts & Figures by Region
  • 3.5.1 Asia Pacific HIV Therapy Sales by Region
  • 3.5.2 Asia Pacific HIV Therapy Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 China Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
• 3.6 Latin America HIV Therapy Market Facts & Figures by Country
  • 3.6.1 Latin America HIV Therapy Sales by Country
  • 3.6.2 Latin America HIV Therapy Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa HIV Therapy Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa HIV Therapy Sales by Country
  • 3.7.2 Middle East and Africa HIV Therapy Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global HIV Therapy Historic Market Analysis by Drug Type

• 4.1 Global HIV Therapy Sales Market Share by Drug Type (2017-2022)
• 4.2 Global HIV Therapy Revenue Market Share by Drug Type (2017-2022)
• 4.3 Global HIV Therapy Price by Drug Type (2017-2022)

5 Global HIV Therapy Historic Market Analysis by Application

• 5.1 Global HIV Therapy Sales Market Share by Application (2017-2022)
• 5.2 Global HIV Therapy Revenue Market Share by Application (2017-2022)
• 5.3 Global HIV Therapy Price by Application (2017-2022)

6 Key Companies Profiled

• 6.1 ViiV Healthcare
  • 6.1.1 ViiV Healthcare Corporation Information
  • 6.1.2 ViiV Healthcare Description and Business Overview
  • 6.1.3 ViiV Healthcare HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.1.4 ViiV Healthcare HIV Therapy Product Portfolio
  • 6.1.5 ViiV Healthcare Recent Developments/Updates
• 6.2 Gilead Sciences, Inc.
  • 6.2.1 Gilead Sciences, Inc. Corporation Information
  • 6.2.2 Gilead Sciences, Inc. Description and Business Overview
  • 6.2.3 Gilead Sciences, Inc. HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.2.4 Gilead Sciences, Inc. HIV Therapy Product Portfolio
  • 6.2.5 Gilead Sciences, Inc. Recent Developments/Updates
• 6.3 GlaxoSmithKline Plc
  • 6.3.1 GlaxoSmithKline Plc Corporation Information
  • 6.3.2 GlaxoSmithKline Plc Description and Business Overview
  • 6.3.3 GlaxoSmithKline Plc HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.3.4 GlaxoSmithKline Plc HIV Therapy Product Portfolio
  • 6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
• 6.4 Merck Sharp & Dohme Corp.
  • 6.4.1 Merck Sharp & Dohme Corp. Corporation Information
  • 6.4.2 Merck Sharp & Dohme Corp. Description and Business Overview
  • 6.4.3 Merck Sharp & Dohme Corp. HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 Merck Sharp & Dohme Corp. HIV Therapy Product Portfolio
  • 6.4.5 Merck Sharp & Dohme Corp. Recent Developments/Updates
• 6.5 Bristol-Myers Squibb Company
  • 6.5.1 Bristol-Myers Squibb Company Corporation Information
  • 6.5.2 Bristol-Myers Squibb Company Description and Business Overview
  • 6.5.3 Bristol-Myers Squibb Company HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.5.4 Bristol-Myers Squibb Company HIV Therapy Product Portfolio
  • 6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
• 6.6 Janssen Pharmaceuticals, Inc.
  • 6.6.1 Janssen Pharmaceuticals, Inc. Corporation Information
  • 6.6.2 Janssen Pharmaceuticals, Inc. Description and Business Overview
  • 6.6.3 Janssen Pharmaceuticals, Inc. HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.6.4 Janssen Pharmaceuticals, Inc. HIV Therapy Product Portfolio
  • 6.6.5 Janssen Pharmaceuticals, Inc. Recent Developments/Updates
• 6.7 Boehringer Ingelheim International GmbH
  • 6.6.1 Boehringer Ingelheim International GmbH Corporation Information
  • 6.6.2 Boehringer Ingelheim International GmbH Description and Business Overview
  • 6.6.3 Boehringer Ingelheim International GmbH HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 Boehringer Ingelheim International GmbH HIV Therapy Product Portfolio
  • 6.7.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
• 6.8 AbbVie Inc.
  • 6.8.1 AbbVie Inc. Corporation Information
  • 6.8.2 AbbVie Inc. Description and Business Overview
  • 6.8.3 AbbVie Inc. HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.8.4 AbbVie Inc. HIV Therapy Product Portfolio
  • 6.8.5 AbbVie Inc. Recent Developments/Updates
• 6.9 Genentech, Inc.
  • 6.9.1 Genentech, Inc. Corporation Information
  • 6.9.2 Genentech, Inc. Description and Business Overview
  • 6.9.3 Genentech, Inc. HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.9.4 Genentech, Inc. HIV Therapy Product Portfolio
  • 6.9.5 Genentech, Inc. Recent Developments/Updates
• 6.10 Mylan N.V.
  • 6.10.1 Mylan N.V. Corporation Information
  • 6.10.2 Mylan N.V. Description and Business Overview
  • 6.10.3 Mylan N.V. HIV Therapy Sales, Revenue and Gross Margin (2017-2022)
  • 6.10.4 Mylan N.V. HIV Therapy Product Portfolio
  • 6.10.5 Mylan N.V. Recent Developments/Updates

7 HIV Therapy Manufacturing Cost Analysis

• 7.1 HIV Therapy Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of HIV Therapy
• 7.4 HIV Therapy Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 HIV Therapy Distributors List
• 8.3 HIV Therapy Customers

9 HIV Therapy Market Dynamics

• 9.1 HIV Therapy Industry Trends
• 9.2 HIV Therapy Market Drivers
• 9.3 HIV Therapy Market Challenges
• 9.4 HIV Therapy Market Restraints

10 Global Market Forecast

• 10.1 HIV Therapy Market Estimates and Projections by Drug Type
  • 10.1.1 Global Forecasted Sales of HIV Therapy by Drug Type (2023-2028)
  • 10.1.2 Global Forecasted Revenue of HIV Therapy by Drug Type (2023-2028)
• 10.2 HIV Therapy Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of HIV Therapy by Application (2023-2028)
  • 10.2.2 Global Forecasted Revenue of HIV Therapy by Application (2023-2028)
• 10.3 HIV Therapy Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of HIV Therapy by Region (2023-2028)
  • 10.3.2 Global Forecasted Revenue of HIV Therapy by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List

Summary:

HIV Therapy involves taking a combination of HIV medicines . HIV Therapy is recommended for everyone who has HIV. HIV Therapy cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.
Industry Insights
Due to the COVID-19 pandemic, the global HIV Therapy market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe HIV Therapy market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe HIV Therapy landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Integrase Inhibitors accounting for % of the HIV Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of HIV Therapy include ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc. and etc. In terms of revenue, the global 3 largest players have a % market share of HIV Therapy in 2021.
This report focuses on HIV Therapy volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall HIV Therapy market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Post-covid-19 Outlook
The readers in the section will understand how the HIV Therapy market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Segmental Outlook
Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
Segment by Drug Type
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Competitive Scenario
In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
Frequently Asked Questions
Which product segment grabbed the largest share in the HIV Therapy market?
How is the competitive scenario of the HIV Therapy market?
Which are the key factors aiding the HIV Therapy market growth?
Which are the prominent players in the HIV Therapy market?
Which region holds the maximum share in the HIV Therapy market?
What will be the CAGR of the HIV Therapy market during the forecast period?
Which application segment emerged as the leading segment in the HIV Therapy market?
What key trends are likely to emerge in the HIV Therapy market in the coming years?
What will be the HIV Therapy market size by 2028?
Which company held the largest share in the HIV Therapy market?